2006
Clinical Cancer Advances 2006: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology
Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, Curran WJ, Eisenberg BL, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Reaman GH, Sawaya R, Schilsky RL, Schuchter LM, Sweetenham JW, Vahdat LT, Winn RJ. Clinical Cancer Advances 2006: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology. Journal Of Clinical Oncology 2006, 25: 146-162. PMID: 17158528, DOI: 10.1200/jco.2006.09.7030.Peer-Reviewed Original ResearchConceptsHuman papillomavirusClinical OncologyHER-2 positive breast cancerCancer researchCancer treatmentScreening—A ReportHalf of menChronic myelogenous leukemiaAmerican SocietyClinical cancer researchCertain common cancersGroup of diseasesBasic science discoveriesASCO recommendationsUseful therapyCervical cancerPreventive vaccineCancer careCancer deathCancer patientsCommon cancerNeck cancerClinical trialsBreast cancerGlobal burdenPhase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer
Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS. Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer. Journal Of Clinical Oncology 2006, 24: 4092-4099. PMID: 16943527, DOI: 10.1200/jco.2005.05.3447.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAntineoplastic AgentsDose-Response Relationship, DrugDrug Administration ScheduleFemaleFlow CytometryGene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticHumansIndolesMaleMiddle AgedNeoplasmsProtein Kinase CProtein Kinase C betaProtein Kinase InhibitorsConceptsMaximum-tolerated doseProtein kinase C beta inhibitorStable diseaseAdvanced cancerEastern Cooperative Oncology Group performance statusSignificant grade 3/4 toxicityBeta inhibitorGrade 3/4 toxicitiesPhase II dosePhase II trialDose-limiting toxicityYears of ageExpansion cohortGI toxicityII trialStarting dosePerformance statusDose escalationAdditional patientsNeck cancerPrevalent malignancySafety dataPatientsSecondary objectiveEnzastaurin
2003
Head and neck cancer
Kies M, Herbst R. Head and neck cancer. 2003, 207-216. DOI: 10.1017/cbo9780511527081.025.Peer-Reviewed Original ResearchSquamous cell cancerNeck malignanciesCell cancerNeck cancerTobacco useNeck squamous cell cancerIndependent risk factorEpstein-Barr virusFloor of mouthConsumption of fruitsDose-response relationshipSynergistic carcinogenic effectUncommon headAdvanced diseaseMost patientsMedian ageAnnual incidenceViral exposureCommon cancerRisk factorsTreatment outcomesIntroduction HeadBuccal mucosaNasopharyngeal carcinomaOral cavity
2002
Novel therapeutics for head and neck cancer
Kim ES, Kies M, Herbst RS. Novel therapeutics for head and neck cancer. Current Opinion In Oncology 2002, 14: 334-342. PMID: 11981281, DOI: 10.1097/00001622-200205000-00014.Peer-Reviewed Original ResearchConceptsNeck squamous cell carcinomaSquamous cell carcinomaNeck cancerSurvival rateCell carcinomaLeading causeEpidermal growth factor receptor blockersAnti-epidermal growth factor receptor monoclonal antibodyNeck squamous cell carcinoma (HNSCC) patientsSquamous cell carcinoma patientsEpidermal growth factor receptor monoclonal antibodiesLong-term survival ratesGrowth factor receptor blockersNovel biologic agentsCell carcinoma patientsMedian survival rateReceptor monoclonal antibodyChemotherapy of headSixth leading causeCancer-related deathFifth leading causeTyrosine kinase inhibitorsFarnesyl transferase inhibitorsProcess of tumorigenesisReceptor blockers